CTSO stock forecast
Our latest prediction for CytoSorbents Corp.'s stock price was made on the Dec. 10, 2019 when the stock price was at 3.88$.
In the short term (2weeks), CTSO's stock price should underperform the market by -6.74%. During that period the price should oscillate between -11.56% and +11.89%.
In the medium term (3months), CTSO's stock price should underperform the market by -19.57%. During that period the price should oscillate between -40.17% and +27.54%.Get email alerts
Create a solid portfolio with CTSO
About CytoSorbents Corp.
CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
At the moment the company generates 24M USD in revenues.
On its last earning announcement, the company reported a loss of -0.65$ per share.
The book value per share is 0.69$
Three months stock forecastDec. 10, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|